Managing bowel obstruction in patients with advanced gynecological cancers
Official title: Risk Stratified Multidisciplinary Ambulatory Management of Malignant Bowel Obstruction (MAMBO) Program for Women With Advanced Gynecological Cancers
Run by University Health Network, Toronto · NCT03260647 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing a new way to manage bowel blockages in patients with advanced gynecological cancers to see if it can improve their care while keeping them out of the hospital.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 100 Years |
| Sex | Women only |
| Enrollment | 150 (estimated) |
| Sponsor | University Health Network, Toronto Academic / other |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT03260647 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with histologically or cytologically confirmed gynecological cancers who are at risk of developing or have a clinical diagnosis of MBO.
✕Probably not a fit
Patients with gynecological cancers who do not exhibit signs of bowel obstruction may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on the management of Malignant Bowel Obstruction (MBO) in patients with advanced gynecological cancers. It aims to develop a collaborative management algorithm that allows for effective treatment in an ambulatory setting, thereby optimizing patient care and resource use. By streamlining the approach to MBO, the study seeks to improve the quality and consistency of care while reducing hospital bed occupancy. The study will include patients with confirmed gynecological cancers who are at risk of or have a clinical diagnosis of MBO.
Why it matters
Potential benefit: If successful, this approach could enhance the quality of care for patients with advanced gynecological cancers experiencing bowel obstruction.
How similar studies have gone: While there is a lack of established guidelines for MBO management in this patient population, the collaborative approach being tested may offer novel insights into effective care.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Histologically and /or cytologically confirmed gynecological cancer, including ovarian, fallopian tube, endometrial, cervical or primary peritoneal cancer Deemed to be at risk of developing or have a clinical diagnosis of MBO as defined using the following criteria: clinical evidence of bowel obstruction (history/physical/radiological examination; and bowel obstruction beyond the ligament of Treitz. Exclusion Criteria: There are no specified exclusion criteria for this study
Where it's running
-
Princess Margaret Cancer Centre
Toronto, Ontario, Canada Recruiting
Study contacts
- Principal investigator: Stephanie Lheureux — University Health Network, Toronto
- Study coordinator: Stephanie L'heureux
- Email: stephanie.lheureux@uhn.ca
- Phone: 416-946-2818
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
NMTCuff vs standard TOF monitoring during gynecologic oncology surgery
This study tests whether NMTCuff monitoring can better detect neuromuscular recovery than standard TOF monitoring in women undergoing laparoscopic gynecologic cancer surgery.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
Personalized supervised exercise program for adults with breast or gynecologic cancer
A small pilot study will test a supervised, personalized exercise program to see if it is safe, feasible, and acceptable for adults with a history of breast or gynecologic cancer.
-
Cesium-131 brachytherapy to preserve organs in recurrent cervical or endometrial cancer
This study tests whether implanting small cesium-131 seeds can provide targeted radiation to vaginal recurrences of cervical or endometrial cancer in patients who previously had pelvic radiation, with the goal of preserving organs.
-
National registry of endometrial cancer cases in Italy
This project will collect clinical and molecular information from adults treated for endometrial cancer at participating Italian oncology centers to see if a national database can improve understanding of outcomes and care.
-
High-precision detection of leftover cancer using a liquid-biopsy platform (SHERLOCK)
This project will test whether sensitive blood and other fluid tests for circulating tumor DNA can find leftover cancer (minimal residual disease) in adults treated with curative intent for breast, lung, melanoma, gynecologic, or genitourinary cancers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.